New hope for rare lung cancer: targeted pill after surgery may stop return

NCT ID NCT05546866

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times

Summary

This study tests whether the drug osimertinib, taken as a pill after surgery, can help prevent lung cancer from coming back in people with a specific rare gene change (uncommon EGFR mutation). About 51 adults with stage IB-IIIB non-small cell lung cancer will take the drug daily for up to 3 years. The main goal is to see how many patients remain cancer-free after 3 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Beijing, 100730, China
Research Site

Chengdu, 610000, China
Research Site

Chengdu, 610041, China
Research Site

Fuzhou, 350011, China
Research Site

Guangzhou, 510080, China
Research Site

Kunming, 650118, China
Research Site

Ningbo, 315010, China
Research Site

Shijiazhuang, 050051, China
Research Site

Suzhou, 215006, China
Research Site

Tianjin, 300060, China

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER